US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
Epigenomics AG (0QXH) 銘柄情報

Epigenomics AG (0QXH)

0.00

0.00

(0.00%)

終了 7月2日 12:30AM

Epigenomics AG (0QXH) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

-

( - )

買値

0.00

売値

0.00

出来高

0.00

0.00 日の範囲 0.00

1.796 52 週間の範囲 1.796

時価総額

前日終値

0.00

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

323 €

発行済株式数

876,976

配当利回り

PER

-2.43

1 株当たり利益 (EPS)

-0.36

歳入

24k

純利益

-314k

Epigenomics AG does not have significant operations. Previously, the company was involved in liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Heidelberg, Germany. Epigenomics AG does not have significant operations. Previously, the company was involved in liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Heidelberg, Germany.

セクター

-

業界

-

ウェブサイト

www.epigenomics.com

本社

Heidelberg, Germany

設立

1998

Epigenomics AG is listed in the sector of the ロンドン証券取引所 with ticker 0QXH. The last closing price for Epigenomics was 0.00 €. Over the last year, Epigenomics shares have traded in a share price range of 1.796 € to 1.796 €.

Epigenomics currently has 876,976 shares in issue. Epigenomics has a price to earnings ratio (PE ratio) of -2.43.

DGAP-PVR: Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the...

DGAP Voting Rights Announcement: Epigenomics AG Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	1.796	1.796	1.796	1	1.796	DE
52	0	0	1.796	1.796	1.796	1	1.796	DE
156	0	0	1.796	1.796	1.796	6	1.796	DE
260	0	0	1.796	1.796	1.796	935	1.796	DE

0QXH - Frequently Asked Questions (FAQ)

What is the current Epigenomics AG share price?

The current share price of Epigenomics AG is 0.00 €

How many Epigenomics AG shares are in issue?

Epigenomics AG has 876,976 shares in issue

What is the 1 year trading range for Epigenomics AG share price?

Epigenomics AG has traded in the range of 1.796 € to 1.796 € during the past year

What is the PE ratio of Epigenomics AG?

The price to earnings ratio of Epigenomics AG is -2.43

What is the cash to sales ratio of Epigenomics AG?

The cash to sales ratio of Epigenomics AG is 31.79

What is the registered address of Epigenomics AG?

The registered address for Epigenomics AG is ZiegelhAeuser Landstrasse 3, Heidelberg, Baden-Württemberg, 69120

What is the Epigenomics AG website address?

The website address for Epigenomics AG is www.epigenomics.com

dewophile

dewophile 2分前

They are also heavily reliant on Dupixent and the COM patent expires in early 2031 so not that far off
Dupixent may also lose share to long acting injectables and orals targeting that pathway

overbore

overbore 4分前

I'll never compain when the share price increases but I'm surprised we didn't see more of a bump. I own shares through TSX and can confrim they did not change. Maybe tomorrow will be another trend upwards. Added more shares today. With this latest EA approval this is a bargain buy right now!

chazzy1

chazzy1 6分前

This text is a standard initial rule in a patent lawsuit. It means the person or company suing (the plaintiff) must formally list the exact products violating their patents, explain how they calculate their financial demands, and share the official government records of how their patent was approved

yadotn

yadotn 12分前

MRNJ>>>-99.92%

MRNJ
INVESTORShub
-99.92%
https://investorshub.advfn.com/stock-market/USOTC/metatron-id-MRNJ/historical

yadotn

yadotn 12分前

MRNJ>>>-99.92%

MRNJ
INVESTORShub
-99.92%

chuck1418

chuck1418 12分前

hold steady. longs gonna win here imo

searay2701

searay2701 13分前

It is now July 1, 2026, this stock’s price situation has not improved but done just the opposite, gone way down from the year it was at $1.50, and down approximately 50% from it’s last low high of $.42, now that is not a sign of a company in it’s best shape ever. This is not, or will it ever be in

gutek

https://www.sec.gov/submit-tip-or-complaint

northam43

northam43 22分前

#1.2 SPX Cycles Expanded Report: Current Cycles Between Cycles (CCBC) is -33 (Extreme Bearish). Extreme Overdue: 60 min (60-2), Daily (D-2), Weekly (W-SC-1).

https://investorshub.advfn.com/uimage/uploads/2026/7/1/jwcnf1_Status_Report.PNG

northam43

northam43 23分前

#1.2 SPX Cycles Expanded Report: Current Cycles Between Cycles (CCBC) is -33 (Extreme Bearish). Extreme Overdue: 60 min (60-2), Daily (D-2), Weekly (W-SC-1).

https://investorshub.advfn.com/uimage/uploads/2026/7/1/jwcnf1_Status_Report.PNG

Eagle1

Eagle1 25分前

Anything under the ATH is a great buy IMO.

Anyone else agree like and share.

TRAPPER JIM

TRAPPER JIM 26分前

Last time I mowed was June 7th. So it’s been a minute

Peeteman

Peeteman 28分前

Evidently when you put everything in caps it makes you more right.

midastouch017

midastouch017 30分前

The life-changing mental health treatment most Americans don’t know exists

https://www.usatoday.com/story/sponsor-story/acumen-usa250/2026/07/01/the-life-changing-mental-health-treatment-most-americans-dont-know-exists/90681643007/

July 1, 2026, 6:01 a.m. ET

FOFreddie

FOFreddie 31分前

Hi Neo, - I dont think I missed the point - we both are making a LOT of assumptions and you most important assumption is that common shareholders will not suffer dilution of any type - warrants - SPS - JPS Conversion. You get a valuation of $ 221 a share for FNMA and an implied valuation of FMCC o

3331

BIEL UPDATE - HUGE - PROFITABLE
BioElectronics Issues Chairman's Update Highlighting Sales Growth, and Strategic Progress

JEFFERSON, MD - June 30, 2026 (NEWMEDIAWIRE) - BioElectronics Corporation (https://www.bielcorp.com/) (OTC: BIEL), a developer of medical technology product

3331

BIEL UPDATE - HUGE - PROFITABLE
BioElectronics Issues Chairman's Update Highlighting Sales Growth, and Strategic Progress

JEFFERSON, MD - June 30, 2026 (NEWMEDIAWIRE) - BioElectronics Corporation (https://www.bielcorp.com/) (OTC: BIEL), a developer of medical technology product

bigsur25

bigsur25 34分前

Trump what are you talking about . He’s got nothing to with Opendoor.

northam43

northam43 35分前

Report #9 SPX Cycles 12 Month Range Forecast: July 2027 projections, current high & low for this month
The projected high range is based on the current year 60 min cycle average.
The projected low range is based on the 60 min cycle averages from 2011 to present

https://i

notshakenorstirred

notshakenorstirred 35分前

https://x.com/TechForce_X/status/2064922811408560324/video/1

northam43

northam43 36分前

Report #9 SPX Cycles 12 Month Range Forecast: July 2027 projections, current high & low for this month
The projected high range is based on the current year 60 min cycle average.
The projected low range is based on the 60 min cycle averages from 2011 to present

https://i

Green Leaf Smoker

Green Leaf Smoker 36分前

Well I'll be damned MJNA goes down! Here's the BEAR link to this POS ....Enough Said
https://investorshub.advfn.com/stock-market/USOTC/medical-marijuana-id-MJNA/trades#google_vignette
.....current Bail Out SP O.OOO1 No Kid wants ones 50% + stock loss 🤣😂🤣

Citrati

Citrati 38分前

Hard for many to wait, however JOBY has still continued to move ahead.

JJ24

Well CEO did say investors should be pleased with the update . I don’t think they would go thru all the trouble to get corrent for fluff news . IMO!

APEX Tech Acquisition

Terra Santa Propriedades... ON

Wolters Kluwer NV (PK)

Sumitomo Realty and Deve... (PK)

BMO Equal Weight Oil and...

Amundi Dow Jones Industr...

First Resource Bancorp (QX)

Bruush Oral Care (EM)

BE Semiconductor Industr... (PK)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。